JAGX On Other Exchanges

jaguar animal health inc (JAGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

jaguar animal health inc (JAGX) Related Businessweek News

No Related Businessweek News Found

jaguar animal health inc (JAGX) Details

Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome - diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera. The company’s animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of various forms of diarrhea in dogs; and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes. In addition, the company's products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. is headquartered in San Francisco, California.

40 Employees
Last Reported Date: 04/10/19

jaguar animal health inc (JAGX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jaguar animal health inc
Jaguar Health, Inc. announced delayed 10-Q filing

On 05/15/2019, Jaguar Health, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Jaguar Health, Inc. Appoints Mayer Hoffman McCann P.C. as the New Independent Registered Public Accounting Firm

On April 29, 2019, Jaguar Health, Inc. with the approval of the Audit Committee (the “Committee”) of the Board of Directors of the company appointed Mayer Hoffman McCann P.C. (“MHM”) as the Company’s new independent registered public accounting firm.

Jaguar Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018

Jaguar Health, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2018. For the quarter, the company reported gross product sales of $2,158,000 against $1,261,000 a year ago. Net product revenue was $1,596,000 against $903,000 a year ago. Net loss from operations was $12,110,000 against $20,681,000 a year ago. For the year, the company reported gross product sales of $5,847,000 against $1,737,000 a year ago. Net product revenue was $4,239,000 against $1,485,000 a year ago. Net loss was $30,824,000 against $34,274,000 a year ago.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

JAGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JAGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation JAGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.3x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JAGUAR ANIMAL HEALTH INC, please visit jaguar.health. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.